David Charles Lubner
CIK 1572000 · Executive VP and CFO · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
11
Total Filings
58
Lifetime Open-Market Net
-$780.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BRVE | Director | 55,555 | — | — | $2.00M | 2 | 2026-08-07 |
| DYN | Director | 0 | $26.00 | $0 | $0 | 9 | 2026-06-09 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
| Arcellx, Inc. (ACLX) Delisted | Director | 0 | $115.07 | $0 | -$450.0K | 7 | 2026-04-28 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 4 | 2025-08-19 |
| VOR | Director | — | $23.28 | — | $0 | 5 | 2025-05-23 |
| POINT Biopharma Global Inc. (PNT) Delisted | Director | 3,600 | $12.50 | $45.0K | $24.7K | 5 | 2023-12-27 |
| Disc Medicine, Inc. (GMTX) Delisted | Director | — | $13.50 | — | $0 | 5 | 2022-03-09 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Executive VP and CFO | 0 | — | — | $0 | 5 | 2020-04-03 |
| NITE | Director | 0 | $39.48 | $0 | $0 | 2 | 2019-06-07 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | SVP and CFO | 3,938 | — | — | -$2.35M | 11 | 2015-08-17 |
Recent Filings · Page 6 of 6
58 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-05-18 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Mixed | — | -$558.8K | EDGAR |
| 2015-01-09 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-10 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −4,510 | -$61.6K | EDGAR |
| 2014-02-13 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −4,506 | -$62.7K | EDGAR |
| 2014-02-11 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Mixed | +78,463 | -$1.7K | EDGAR |
| 2014-01-10 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-17 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-03-27 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Conv (C) | +10,297 | $0 | EDGAR |
Showing 51–58 of 58
Prev
Page 6 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.